Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Quote. Delayed Nasdaq - 01/21 04:00:00 pm
422.1 USD   -2.89%
01/21INSIDER SELL : Dexcom
MT
01/19DexCom Shares Rise After Wells Fargo Upgrade
MT
01/19Raymond James Adjusts DexCom's Price Target to $538 from $618, Keeps Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Dexcom

11/16/2021 | 03:22pm EST


© MT Newswires 2021
All news about DEXCOM, INC.
01/21INSIDER SELL : Dexcom
MT
01/19DexCom Shares Rise After Wells Fargo Upgrade
MT
01/19Raymond James Adjusts DexCom's Price Target to $538 from $618, Keeps Outperform Rating
MT
01/19Wells Fargo Upgrades DexCom to Overweight From Equalweight; Price Target is $575
MT
01/11UBS Adjusts DexCom Price Target to $640 From $660, Maintains Buy Rating
MT
01/10Health Care Stocks Slip Premarket Monday
MT
01/10DexCom Issues Q4, Full Year 2021 Revenue Guidance
MT
01/10DEXCOM : Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Da..
PU
01/10DEXCOM INC : Results of Operations and Financial Condition, Other Events, Financial Statem..
AQ
01/10Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and ..
CI
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Financials (USD)
Sales 2021 2 450 M - -
Net income 2021 249 M - -
Net Debt 2021 136 M - -
P/E ratio 2021 170x
Yield 2021 -
Capitalization 40 911 M 40 911 M -
EV / Sales 2021 16,8x
EV / Sales 2022 13,6x
Nbr of Employees 5 500
Free-Float 98,6%
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 422,10 $
Average target price 611,56 $
Spread / Average Target 44,9%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain SVP-Finance, Chief Financial & Accounting Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategy
Jacob S. Leach Chief Technology Officer & Executive VP
Shelly R. Selvaraj Senior Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.-21.39%40 911
ABBOTT LABORATORIES-10.59%215 794
MEDTRONIC PLC2.57%141 985
BECTON, DICKINSON AND COMPANY5.23%75 431
HOYA CORPORATION-11.34%49 186
BAXTER INTERNATIONAL INC.0.51%43 200